<?xml version="1.0" encoding="UTF-8"?>
<p id="p0010">Zika virus (ZIKV) is a mosquito-borne flavivirus that can cause devastating microcephaly and other congenital syndromes in infants born to infected pregnant women as well as Guillain-Barré syndrome in infected adults.
 <xref rid="bib1" ref-type="bibr">
  <sup>1</sup>
 </xref> In this issue of 
 <italic>Molecular Therapy</italic>, Sariyer et al.
 <xref rid="bib2" ref-type="bibr">
  <sup>2</sup>
 </xref> present evidence demonstrating that rilpivirine, a US Food and Drug Administration (FDA)-approved HIV drug, inhibits ZIKV RNA-dependent RNA polymerase (RdRp), leading to potent anti-ZIKV activity in cell cultures and mice. The study highlights the potential of repurposing clinically approved drugs for possible prevention and treatment of ZIKV infection and its associated disease.
</p>
